FIELD: biotechnology.
SUBSTANCE: invention relates to scDNA vectors having a linear and continuous structure for transgene delivery and expression; scDNA vectors contain an expression cassette flanked by two ITR sequences, the expression cassette encodes a transgene. Some scDNA vectors additionally contain cis regulatory elements, including regulatory switches. This document further provides methods and cell lines for robust gene expression in vitro, ex vivo and in vivo using scDNA vectors. Methods and compositions containing scDNA vectors useful for expressing an antibody or fusion protein in a cell, tissue, or subject are provided in this document.
EFFECT: such antibodies or fusion proteins may be expressed to treat a disease or, alternatively, to produce antibodies or fusion proteins commercially.
43 cl, 12 dwg, 13 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NON-VIRAL DNA VECTORS AND OPTIONS FOR THEIR USE FOR EXPRESSION OF THERAPEUTIC AGENT BASED ON PHENYLALANINE HYDROXYLASE (PAH) | 2020 |
|
RU2814137C2 |
| CLOSED-ENDED DNA VECTORS OBTAINED BY CELL-FREE SYNTHESIS, AND METHOD OF PRODUCING CEDNA VECTORS | 2019 |
|
RU2820586C2 |
| MODIFIED CLOSED CIRCULAR DNA (CCDNA) CONTAINING SYMMETRIC MODIFIED INVERTED END REPEATED SEQUENCES | 2019 |
|
RU2816963C2 |
| NON-VIRAL DNA VECTORS AND OPTIONS FOR THEIR USE FOR EXPRESSION OF THERAPEUTIC AGENT BASED ON FACTOR VIII (FVIII) | 2020 |
|
RU2812852C2 |
| MODIFIED CLOSED-ENDED DNA (scDNA) | 2018 |
|
RU2800026C2 |
| CONTROLLED EXPRESSION OF TRANSGENES USING CLOSED-END DNA VECTORS (ceDNA) | 2019 |
|
RU2816871C2 |
| GENE EDITING USING MODIFIED CLOSED-END DNA (ceDNA) | 2018 |
|
RU2811724C2 |
| MODULATION OF REP PROTEIN ACTIVITY WHEN PRODUCING CLOSED-END DNA (ceDNA) | 2020 |
|
RU2812850C2 |
| COMPOSITIONS OF NON-VIRAL NON-CAPSID DNA VECTORS BASED ON LIPID NANOPARTICLES | 2018 |
|
RU2778407C2 |
| GENE EDITING OF DEEP INTRON MUTATIONS | 2016 |
|
RU2759335C2 |
